Xylem (NYSE:XYL) 주식

Xylem

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.

Xylem Inc

XY Labs Inc

Global X Funds Global X S&P 500 Covered Call ETF

Global X Funds S&P 500 Esg Covered Call ETF

Global X S&P 500 Covered Call & Growth ETF

Xylo Technologies Ltd. - American Depositary Shares

Xylo Technologies Ltd

Sweet Natural Trading Co Ltd

Throughout the last three months, 6 analysts have evaluated Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $142.67, a high estimate of $148.00, and a low estimate of $134.00. This current average represents a 2.81% decrease from the previous average price target of $146.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1748610038_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Xylem among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$148.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$141.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$146.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$134.00</td>
<td>$152.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xylem. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Xylem compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Xylem's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Xylem's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/XYL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Xylem analyst ratings.</a>
<h2>Unveiling the Story Behind Xylem</h2>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.
<h3>Financial Milestones: Xylem's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3M period, Xylem showcased positive performance, achieving a revenue growth rate of 1.77% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Xylem's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.58%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Xylem's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.02%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Xylem's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.2.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Where Xylem Stands With Analysts

JP Morgan analyst Mark Strouse initiates coverage on Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Overweight rating and announces Price Target of $148.

News

Price Target

Initiation

JP Morgan Initiates Coverage On Xylem with Overweight Rating, Announces Price Target of $148

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) has outperformed the market over the past 10 years by 2.4% on an annualized basis producing an average annual return of 13.17%. Currently, Xylem has a market capitalization of $31.16 billion. 
Buying $1000 In XYL: If an investor had bought $1000 of XYL stock 10 years ago, it would be worth $3,478.13 today based on a price of $128.03 for XYL at the time of writing.
<h3>Xylem's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747434613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Xylem 10 Years Ago Would Be Worth Today

WIIM

Advanced Environmental Recycling Technologies

AERT

BGLC

BGSF

BLDR

CARR

CLWT

CSWI

ELWS

EVTL

FBIN

FTAI

FWRD

HKPD

KELYB

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MVST

REZI

RKLB

RUSHA

RUSHB

SFHG

TGLS

TREX

USEA

Shares of companies in the broader industrial sector are trading higher amid overall market strength after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could reduce macro uncertainty that has weighed on economic outlook.

Xylem's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) short percent of float has fallen 10.73% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 1.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.23 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Xylem Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746453621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Xylem has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Xylem's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Xylem's peer group average for short interest as a percentage of float is 3.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Xylem's Recent Short Interest

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) has outperformed the market over the past 10 years by 2.32% on an annualized basis producing an average annual return of 12.7%. Currently, Xylem has a market capitalization of $29.39 billion. 
Buying $100 In XYL: If an investor had bought $100 of XYL stock 10 years ago, it would be worth $329.56 today based on a price of $120.76 for XYL at the time of writing.
<h3>Xylem's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746143115_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

RBC Capital analyst Deane Dray maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and raises the price target from $143 to $147.

RBC Capital Maintains Outperform on Xylem, Raises Price Target to $147

Stifel analyst Nathan Jones maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy and raises the price target from $140 to $141.

Stifel Maintains Buy on Xylem, Raises Price Target to $141

Baird analyst Michael Halloran maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and lowers the price target from $149 to $146.

Baird Maintains Outperform on Xylem, Lowers Price Target to $146

Wall Street rose modestly by midday Tuesday, as investors weighed the latest developments in trade negotiations and awaited a wave of key economic data and corporate earnings set for <a href="https://www.benzinga.com/25/04/45072497/us-trade-deficit-explodes-to-record-162-billion-in-march-as-import-frenzy-precedes-trumps-tariff-barrage">release later this week.</a>
President Donald Trump is <a href="https://apnews.com/article/trump-tariffs-automakers-factories-relief-25a400c98e02c01c8c54502384e267e1">expected</a> to unveil a new executive order on auto tariffs later today. Meanwhile, U.S. Treasury Secretary Bessent added that the administration is pursuing bilateral trade agreements with 17 major partners, excluding China.
The S&amp;P 500 climbed 0.4%, putting it on track for a sixth consecutive gain—its longest winning streak since November 2024.
In the bond market, U.S. Treasuries extended their rally, with yields falling for a sixth straight session. The yield on the 10-year benchmark dropped to 4.17%, marking a two-week low.
Gold prices slipped 0.6% to $3,325 per ounce, while WTI crude oil futures fell 2.4% to $60 per barrel, the lowest level in two weeks. Oil prices are under pressure from escalating global trade tensions and weaker U.S. economic data, and crude is now on track for a 15% decline in April—its steepest monthly drop since 2021.
Bitcoin traded little changed, around $95,000.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,513.32</td>
<td>+285.73</td>
<td>0.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,548.89</td>
<td>+20.14</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,468.38</td>
<td>+41.09</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,969.38</td>
<td>+3.83</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.4% up to $552.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.7% to $404.9.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.3% higher to $473.78.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $195.96.</li>
<li>The&nbsp;Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 0.8%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
Stocks moving on earnings report included:
<ul>
<li>Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>): down 0.6%</li>
<li>Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>): up 4.0%</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>): down 6.3%</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): up 0.9%</li>
<li>F5 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>): down 0.9%</li>
<li>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>): down 6.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>): down 1.0%</li>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 2.7%</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>): up 5.0%</li>
<li>American Tower Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>): up 4.3%</li>
<li>Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>): up 5.2%</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): down 7.7%</li>
<li>Zebra Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>): up 6.1%</li>
<li>Ecolab, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 2.2%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>): up 1.6%</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>): up 2.3%</li>
<li>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>): down 1.6%</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>): down 0.5%</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>): down 0.7%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): up 1.9%</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): up 4.4%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 0.8%</li>
<li>Sysco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>): up 0.4%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 1.5%</li>
<li>Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): up 1.5%</li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>): up 0.7%</li>
<li>Corning, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>): up 2.5%</li>
<li>Paccar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>): down 3.0%</li>
<li>A.O. Smith Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>): up 4.0%</li>
<li>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>): up 0.5%</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): down 1.4%</li>
</ul>
Stocks slated to report earnings after the bell include Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>), Veralto Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Extendicare Inc. (TSE: EXE), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Boston Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>), PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>), Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>), ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), Regency Centers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), and Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>).
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Economics

ETFs

ACGL

BKNG

CDNS

CSGP

SPDR Dow Jones Industrial Average ETF Trust

FFIV

FICO

FSLR

INCY

Laboratory Corporation Of America Holdings

MDLZ

PCAR

PYPL

REGN

SBUX

SPGI

VLTO

Select Sector SPDR-Consumer Discretionary

ZBRA

Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?

Xylem Says It Is Offsetting The Current Tariff Impacts With 'Strategic Pricing' And 'Proactive Supply Chain Management'

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) affirms FY2025 Adj EPS guidance from $4.50-$4.70 to $4.50-$4.70 vs $4.63 analyst estimate. Raises FY2025 sales outlook from $8.60 billion-$8.70 billion to $8.70 billion-$8.80 billion vs $8.74 billion estimate.

Guidance

Xylem Affirms FY2025 Adj EPS Guidance of $4.50-$4.70 vs $4.63 Est; Raises FY2025 Sales Guidance from $8.60B-$8.70B to $8.70B-$8.80B vs $8.74B Est

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.95 by 8.42 percent. This is a 14.44 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $2.07 billion which beat the analyst consensus estimate of $2.04 billion by 1.43 percent. This is a 1.77 percent increase over sales of $2.03 billion the same period last year.

Earnings

Earnings Beats

Xylem Q1 Adj. EPS $1.03 Beats $0.95 Estimate, Sales $2.07B Beat $2.04B Estimate

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

ATRC

BBIO

BBVA

BGFV

BRSP

CECO

CHCT

CLVT

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FOUR

FRSH

FRST

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Xylem will report an earnings per share (EPS) of $0.95. 
Anticipation surrounds Xylem's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat EPS by $0.05, which was followed by a 0.44% increase in the share price the next day.
Here's a look at Xylem's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.13</td>
<td>1.11</td>
<td>1.06</td>
<td>0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.18</td>
<td>1.11</td>
<td>1.09</td>
<td>0.90</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745852624_0.png" alt="eps graph" />
<h3>Market Performance of Xylem's Stock</h3>
Shares of Xylem were trading at $116.1 as of April 25. Over the last 52-week period, shares are down 10.49%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Views on Xylem</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Xylem.
Analysts have provided Xylem with 3 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $140.67, suggesting a potential 21.16% upside.
<h3>Comparing Ratings with Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Ingersoll Rand, Fortive and Dover, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Ingersoll Rand, with an average 1-year price target of $93.0, suggesting a potential 19.9% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Fortive, with an average 1-year price target of $79.67, suggesting a potential 31.38% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Dover, with an average 1-year price target of $205.54, suggesting a potential 77.04% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary presents essential metrics for Ingersoll Rand, Fortive and Dover, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylem</td>
<td>Buy</td>
<td>6.52%</td>
<td>$857M</td>
<td>3.07%</td>
</tr>
<tr>
<td>Ingersoll Rand</td>
<td>Outperform</td>
<td>4.24%</td>
<td>$815.40M</td>
<td>2.25%</td>
</tr>
<tr>
<td>Fortive</td>
<td>Neutral</td>
<td>2.31%</td>
<td>$977.20M</td>
<td>2.01%</td>
</tr>
<tr>
<td>Dover</td>
<td>Neutral</td>
<td>-0.94%</td>
<td>$745.50M</td>
<td>3.28%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Xylem ranks first in revenue growth among its peers. It also leads in gross profit margin. However, it ranks second in return on equity.
<h3>All You Need to Know About Xylem</h3>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.
<h3>Breaking Down Xylem's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Xylem showcased positive performance, achieving a revenue growth rate of 6.52% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.45%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Xylem's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.07%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Xylem's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 2.0%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Xylem's debt-to-equity ratio is below the industry average. With a ratio of 0.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/XYL/earnings">To track all earnings releases for Xylem visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Xylem's Earnings Expectations

Ratings for Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $143.0, with a high estimate of $150.00 and a low estimate of $134.00. Observing a downward trend, the current average is 5.77% lower than the prior average price target of $151.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744812046_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Xylem by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Nathan Jones &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $140.00&#x7C;$150.00 &#x7C; 
&#x7C;Andrew Kaplowitz &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $134.00&#x7C;$152.00 &#x7C; 
&#x7C;Michael Halloran &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $148.00&#x7C;$139.00 &#x7C; 
&#x7C;Nathan Jones &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$166.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xylem. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Xylem compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Xylem's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Xylem's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/XYL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Xylem analyst ratings.</a>
<h2>Discovering Xylem: A Closer Look</h2>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.
<h3>Xylem: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Xylem's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 6.52%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Xylem's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 14.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Xylem's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.07%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.0%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Xylem's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.2.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Xylem Stock: Analyst Perspectives (4 Ratings)

Stifel analyst Nathan Jones maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy and lowers the price target from $150 to $140.

Stifel Maintains Buy on Xylem, Lowers Price Target to $140

Citigroup analyst Andrew Kaplowitz maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Buy and lowers the price target from $152 to $134.

Citigroup Maintains Buy on Xylem, Lowers Price Target to $134

AGCO

ATMU

CMCO

CVGI

GTES

GTLS

HLIO

JBTM

LECO

MIDD

NDSN

RAIL

TWIN

Shares of machinery companies are trading lower as stocks pull back after surging Wednesday following President Trump's tariff pause announcement.

ALSN

BLBD

EPAC

ESAB

FSTR

OTIS

PDYN

PRLB

SPXC

UGRO

WPRT

Shares of machinery companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

Press Releases

Matthew Pine, President and Chief Executive Officer of Xylem, Joins Trane Technologies Board of Directors

Commodities

Permascand and Magneto Special Anodes merge to create a global leader in the advanced electrochemical sector - David Ekberg joins as CEO of the new company

Communities, Businesses, and NGOs Unite to Tackle Water Challenges for World Water Day 2025

Comments

Xylem

뉴스

파트너 / 기고자

벤징가 글로벌